Company Overview

Update
Headquarters:
San Diego, CA
Funding:
$1.10M
Categories:
Biotechnology

MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.

Description

Update

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory... See More

Current Team (2)

Update

Funding Rounds (1) - $1.10M

Update
  • $1.10M

    Investors Unknown
    May 31, 2011 -Unknown

Offices/Locations (1)

Update
  • Office

    11975 El Camino Real, Suite 101

    San Diego, CA 92130

    USA

Images (1)

Update
  • Cf1cae8f12556a472c8f530ff958fb12